Loading
NASDAQHealthcareBiotechnology
Latest quote
$26.14
+$0.82 · +3.24%
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Previous close
$26.14
+$0.82 · +3.24%
After-hours
$26.14
$0.00 · 0.00%
Sep 4, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Day range
Current $26.14
52-week range
Current $26.14
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
33
Expensive
Sentiment
72
Bullish
Risk
52
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Day range
Current $26.14
52-week range
Current $26.14
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 83.98M USD | 54.55M USD | 76.99M USD | 38.63M USD | 29.75M USD |
| Cost of goods sold | 18.86M USD | 221.63M USD | 189.15M USD | 184.5M USD | 116.43M USD |
| Gross profit | 65.12M USD | −167.08M USD | −112.16M USD | −145.87M USD | −86.68M USD |
| Research and development | 308.16M USD | 221.63M USD | 189.15M USD | 184.5M USD | 116.43M USD |
| Selling, general, and administrative | 52.74M USD | 45.94M USD | 42.9M USD | 38M USD | 31.2M USD |
| Operating expenses | 350.79M USD | 45.94M USD | 42.9M USD | 38M USD | 31.2M USD |
| Interest income | 21.97M USD | 19.73M USD | 11.12M USD | 3.51M USD | 823K USD |
| Depreciation and amortization | 18.86M USD | 8.02M USD | 6.13M USD | 4.15M USD | 1.99M USD |
| Operating income | −285.67M USD | −213.03M USD | −155.06M USD | −183.87M USD | −117.89M USD |
| Net income | −264.46M USD | −193.57M USD | −143.95M USD | −180.36M USD | −117.19M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$34.67
32.63% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI76.36M0.00%2.3T USD0.03%$379.73-0.32%
State Street SPDR S&P Biotech ETFXBI66.47M0.58%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM64.26M0.08%79.88B USD0.19%$296.01+0.28%
ARK Genomic Revolution ETFARKG44.86M2.23%1.56B USD0.75%$47.14-0.13%
Vanguard Extended Market ETFVXF26M0.03%93.7B USD0.05%$242.66+0.14%
iShares Biotechnology ETFIBB18.99M0.18%10.72B USD0.44%$211.92-0.88%
iShares Russell 2000 Growth ETFIWO17.64M0.12%14.58B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO12.49M0.07%17.4B USD0.06%$119.62+0.25%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMARK Genomic Revolution ETFARKGVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
